• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Kestra Showcases Real-World Outcomes for ASSURE WCD at Heart Rhythm 2025

    4/29/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care
    Get the next $KMTS alert in real time by email

    KIRKLAND, Wash., April 29, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) ("Kestra"), a wearable medical device and digital healthcare company, today announced the presentation of new real-world data on the ASSURE® Wearable Cardioverter Defibrillator (WCD) at Heart Rhythm 2025, the annual meeting of the Heart Rhythm Society (HRS), held April 24–27 in San Diego.

    The abstract, titled "Real-world Experience with a Novel Wearable Cardioverter Defibrillator in a Community Setting: Advanced Practice Provider-Driven Care Model," was developed in partnership with Ashley L. Dailey, ANP-BC, MSN and Opesanmi O. Esan, MD, and presented at the annual meeting. The abstract examined outcomes in a nonprofit, community-based medical center using an advanced practice provider (APP)-driven protocol for WCD therapy—one of the first analyses of its kind.

    "The data reinforce how the ASSURE system supports meaningful protection from sudden cardiac arrest through both clinical performance and patient engagement—particularly in real-world, community care settings," said Brian Webster, President and Chief Executive Officer of Kestra. "We were proud to see this work highlighted at HRS."

    Key Findings from the Abstract

    The analysis revealed high patient compliance, with a median daily wear time of 23.3 hours and consistent usage, often extending beyond 90 days—highlighting the importance of sustained device use in protecting patients at risk of sudden cardiac death.

    Notably, ventricular arrhythmias were detected in 4% of patients, even within a predominantly primary prevention population, underscoring the importance of real-time monitoring and early intervention. Among those who received therapy, the outcomes reflect effective continuity of care—with patients benefiting from timely escalation through ICD placement or hospitalization.

    Additionally, the study highlighted how an APP-driven care model successfully delivered WCD therapy in alignment with guideline-based recommendations—ensuring that all indicated patients received appropriate care and demonstrating the value of structured, team-based approaches in expanding access and improving outcomes within a community-based setting. View the full abstract here.

    The presentation marked another milestone for Kestra and its mission to expand access to intelligent, connected cardiac recovery solutions across all levels of care.

    About Kestra

    Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com.



    Media contact
    Rhiannon Pickus
    [email protected]
    
    Investor contact
    Neil Bhalodkar
    [email protected]

    Primary Logo

    Get the next $KMTS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $KMTS

    DatePrice TargetRatingAnalyst
    3/31/2025$30.00Buy
    BofA Securities
    3/31/2025$29.00Outperform
    Wolfe Research
    3/31/2025$24.00Neutral
    Goldman
    3/31/2025$28.00Buy
    Stifel
    3/31/2025$28.00Overweight
    Wells Fargo
    3/31/2025$27.00Overweight
    Piper Sandler
    More analyst ratings

    $KMTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kestra Medical Technologies, Ltd. to Report Fourth Quarter and Fiscal Year 2025 Results on July 15

      KIRKLAND, Wash., July 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced that it will report fourth quarter and fiscal year 2025 financial results on Tuesday, July 15. Management will host a corresponding conference call at 4:30 p.m. Eastern Time. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digit

      7/1/25 8:00:00 AM ET
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

      BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

      6/23/25 9:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Kestra Medical Technologies Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

      KIRKLAND, Wash., June 23, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced that the company will be added to the Russell 3000® Index, with automatic inclusion in the Russell 2000® Index, effective after the U.S. market close on June 27. The annual reconstitution of the Russell indexes captures the 4,000 largest U.S. stocks as of April 30, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index results in automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index and the appropriate growth and value style indexes. Russell in

      6/23/25 8:00:00 AM ET
      $KMTS
      Medical/Dental Instruments
      Health Care

    $KMTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities initiated coverage on Kestra Medical Technologies with a new price target

      BofA Securities initiated coverage of Kestra Medical Technologies with a rating of Buy and set a new price target of $30.00

      3/31/25 8:54:18 AM ET
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Wolfe Research initiated coverage on Kestra Medical Technologies with a new price target

      Wolfe Research initiated coverage of Kestra Medical Technologies with a rating of Outperform and set a new price target of $29.00

      3/31/25 8:13:51 AM ET
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on Kestra Medical Technologies with a new price target

      Goldman initiated coverage of Kestra Medical Technologies with a rating of Neutral and set a new price target of $24.00

      3/31/25 8:13:51 AM ET
      $KMTS
      Medical/Dental Instruments
      Health Care

    $KMTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

      BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

      6/23/25 9:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Kestra Medical Technologies Announces Appointment of Conor Hanley to its Board of Directors

      KIRKLAND, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Conor Hanley as an independent director to its board, effective June 4, 2025. "I am delighted to welcome Conor to our board of directors," said Brian Webster, President and CEO of Kestra Medical Technologies. "He brings deep expertise in medical technology and cardiac care and will serve as an invaluable strategic resource as we grow and expand the reach of the ASSURE® system." Mr. Hanley is a chartered director and currently serves as CEO of FIRE1, a venture-backed connected medical device sol

      6/5/25 8:00:00 AM ET
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

      Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son

      4/3/25 11:00:00 AM ET
      $BSX
      $KMTS
      Medical/Dental Instruments
      Health Care

    $KMTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Hanley Conor

      3 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

      6/12/25 4:23:02 PM ET
      $KMTS
      Medical/Dental Instruments
      Health Care

    $KMTS
    SEC Filings

    See more
    • SEC Form 8-K filed by Kestra Medical Technologies Ltd.

      8-K - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

      6/6/25 6:08:27 AM ET
      $KMTS
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13G filed by Kestra Medical Technologies Ltd.

      SCHEDULE 13G - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Subject)

      5/15/25 5:15:21 PM ET
      $KMTS
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13G filed by Kestra Medical Technologies Ltd.

      SCHEDULE 13G - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Subject)

      5/15/25 4:05:32 PM ET
      $KMTS
      Medical/Dental Instruments
      Health Care

    $KMTS
    Financials

    Live finance-specific insights

    See more
    • Kestra Medical Technologies, Ltd. to Report Fourth Quarter and Fiscal Year 2025 Results on July 15

      KIRKLAND, Wash., July 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced that it will report fourth quarter and fiscal year 2025 financial results on Tuesday, July 15. Management will host a corresponding conference call at 4:30 p.m. Eastern Time. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digit

      7/1/25 8:00:00 AM ET
      $KMTS
      Medical/Dental Instruments
      Health Care
    • Kestra Medical Technologies, Ltd. to Report Third Quarter Fiscal 2025 Financial Results on April 14

      KIRKLAND, Wash., April 02, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced that it will report financial results for the third quarter fiscal 2025 on Monday, April 14. Management will host a corresponding conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable

      4/2/25 4:05:00 PM ET
      $KMTS
      Medical/Dental Instruments
      Health Care